A Rollover Protocol for Subjects Previously Treated With AGS-003

Status:
Terminated

Trial end date:
2018-05-01

Target enrollment:

Participant gender:

The purpose of this study is to evaluate clinical response to AGS-003 alone or in combination with sunitinib therapy.

Phase 2

Argos Therapeutics